,i #aaeth ,,congress #ast ,session ,h4 ,r4 #bjbf ,,in ,,the ,,house ,,of ,,representatives ,april #f1 #bjag,mr4 ,guthrie introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to improve patient access to emerging medication therapies by clarifying the scope of permitted health care economic and scientific information communications between biopharmaceutical manufacturers and population health decision makers4 #a4 ,short title ,this ,act may be cited as the ,pharmaceutical ,information ,exchange ,act4 #b4 ,facilitating exchange of information prior to approval ,section #ejb7;a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #ceb7;a77 is amended-- 7#a7 by redesignating subparagraph 7#b7 as subparagraph 7#c72 7#b7 by inserting after subparagraph 7#a7 the following3 7#b7 ,health care economic information or scientific information provided to a payor1 formulary committee1 or other similar entity with knowledge and expertise in the area of health care economic analysis carrying out its responsibilities for the selection of drugs for coverage1 reimbursement1 or other population-based health care management1 shall not be considered false or misleading or any other form of misbranding under this paragraph1 or a violation of section #eje of this ,act or section #cea of the ,public ,health ,service ,act1 or otherwise prohibited pre-approval promotion of a drug1 if it is based on competent and reliable scientific evidence and relates to an investigational new drug or an investigational use of an approved drug4 ,in order for information relating to an investigational use of an approved drug to be provided pursuant to this subparagraph1 there must have been submitted to the ,secretary a supplemental application for approval of such use1 or the study or studies needed to support the submission of a supplemental application for such use must have been completed with the intention that a supplemental application will be submitted to the ,secretary for approval of the use4 ,for purposes of this subparagraph1 scientific information includes clinical and pre-clinical data and results relating to an unapproved drug therapy1 or drug indication1 or other condition of use being investigated or developed4 2 and 7#c7 in subparagraph 7#c71 as redesignated-- 7,a7 by striking 7,a72 and 7,b7 by striking clause 7,b74